Disease
Bone and soft tissue sarcoma骨与软组织肉瘤
ICD-10: C40, C41, C47, C49 — Malignant neoplasm of bone and articular cartilage of limbs
Key figures
Published values only. Every tile opens the section that carries its source, its year and its caliber.
Disease details
- Standard Chinese name
- 骨与软组织肉瘤
- English name
- Malignant neoplasm of bone and articular cartilage of limbs
Values written in Chinese are quoted as published by the source.
Also known as
- Bone and soft tissue sarcoma
- Bone sarcoma
- Soft tissue sarcoma
- Osteosarcoma
Treatment cost ranges
Every range below is published on one billing basis: Pre-reimbursement 医保报销前. The sources publish no post-reimbursement figure, so none is shown here.
| Treatment path | Cost range | Price basis | Data year |
|---|---|---|---|
| Surgery 手术 | 47500 – 47500 CNY | Condition package price 病种打包全包价 | 2018 |
| Surgery 手术 | 15200 – 15200 CNY | Condition package price 病种打包全包价 | 2018 |
The bars share one scale across the rows above: each starts at that row's lower published figure and ends at its upper one. The highest upper figure on this page is 47500 CNY. Each row keeps its own data year and caliber.
2 cost ranges for this condition, each with its source on the row page.
Values written in Chinese are quoted as published by the source.
Five-year survival
5-year survival rate 39.5%
- Population
- Bone · Overall (all stages combined) · Age-standardised relative survival 骨 · 总体（全分期合并）· 年龄标准化相对生存率
- Period
- 2019–2021
- Publisher
- National Cancer Center 国家癌症中心
- Value nature
- Estimated value (hybrid analysis) 估计值（混合法）
- Registry scope
- 281 population-based cancer registries 281 个肿瘤登记处
- Stage data availability
- Not published
Values written in Chinese are quoted as published by the source.
How to read this figure. It is published for all stages combined, so it is an average over everyone in the national registry data rather than a prognosis for one person. For most cancers, the stage at diagnosis is the strongest single factor behind survival differences: survival is generally higher when the cancer is found at an earlier stage and lower when it is found later. Comparisons between cancers are also shaped by how early or late each one tends to be diagnosed, so a lower figure does not by itself mean worse care.
Hospitals with a published record for this condition
Selected using official public data sources
These hospitals are selected from official public data sources — the Fudan University hospital specialty reputation rankings, the national key clinical specialties list and national clinical research centres — so each line on a card can be checked against its published source. This is not a paid or promoted listing.
How these hospitals were selected
Admission. A hospital is listed for a condition when the specialty that condition is filed under carries at least one of: a place or a nomination in the Fudan University hospital specialty reputation ranking; a national key clinical specialty record at level A, B or C; or a national clinical research centre or a state key laboratory in that specialty. JCI accreditation is shown as a badge; it never decides admission and it never decides order.
Order. Step 1: a Fudan place between 1 and 10 for the specialty. Step 2: another Fudan place, or a nomination. Step 3: a level-A national key clinical specialty. Step 4: a level-B national key clinical specialty. Step 5: a national clinical research centre or a state key laboratory in the specialty, a centre before a laboratory. Step 6: a level-C national key clinical specialty, which is a record we publish without an independent official source and which is therefore listed after the others.
Ties. Within one step: the better Fudan place first, then the stronger key-specialty level (A before B before C), then the province, then the city, then the hospital name - the same province-city-name order the hospital directory uses. At most eight hospitals are listed.
When the list is short. Five hospitals or more: the first eight are listed. Three or four: all of them are listed, and a further fold adds the remaining records up to eight, each carrying its evidence level. One or two: the same, with that fold open and a line stating how many hospitals have a strong public record. None: the page states that no strong public record was found and links to the specialty directory. A place, an institution or a count is never invented to fill the list.
The Fudan rankings are the hospital specialty reputation ranking most widely recognised by Chinese clinicians, published annually by Fudan University's hospital management institute.
-
Cancer Hospital of Chinese Academy of Medical Sciences中国医学科学院肿瘤医院
Fudan specialty reputation ranking 2023
- Medical Oncology #1 https://www.fdygs.com/news2023-1.aspx
National key clinical specialty
- Medical Oncology (level B) https://www.cicams.ac.cn/news/401.html
Research platform
- 国家恶性肿瘤临床医学研究中心 https://www.most.gov.cn/tztg/201306/t20130608_106459.html
Also ranked: Thoracic Surgery #1, Urology nominated in the Fudan list.
-
Sun Yat-sen University Cancer Center中山大学肿瘤防治中心
Fudan specialty reputation ranking 2023
- Medical Oncology #2 https://www.fdygs.com/news2023-1.aspx
National key clinical specialty
- Medical Oncology (level B) https://www.sysucc.org.cn/node/8565
Also ranked: Thoracic Surgery #9 in the Fudan list.
-
Fudan University Shanghai Cancer Center复旦大学附属肿瘤医院
Fudan specialty reputation ranking 2023
- Medical Oncology #3 https://www.fdygs.com/news2023-1.aspx
National key clinical specialty
- Medical Oncology (level B) https://www.shca.org.cn/home/news/content/id/297/pid/25651
Also ranked: Thoracic Surgery #10, Nuclear Medicine 核医学 nominated in the Fudan list.
-
Peking University Cancer Hospital北京大学肿瘤医院
Fudan specialty reputation ranking 2023
- Medical Oncology #4 https://www.fdygs.com/news2023-1.aspx
National key clinical specialty
- Medical Oncology (level B) https://www.bjcancer.org/Html/Hospitals/Main/Description.html
Also ranked: Nuclear Medicine 核医学 nominated in the Fudan list.
-
Tianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院
Fudan specialty reputation ranking 2023
- Medical Oncology #5 https://www.fdygs.com/news2023-1.aspx
National key clinical specialty
- Medical Oncology (level B) https://www.tjmuch.com/yygk/yyjj/index_yg.shtml
-
Shandong Cancer Hospital山东省肿瘤医院暨山东省肿瘤防治研究院
Fudan specialty reputation ranking 2023
- Medical Oncology #6 https://www.fdygs.com/news2023-1.aspx
-
Zhejiang Cancer Hospital中国科学院大学附属肿瘤医院（浙江省肿瘤医院）
Fudan specialty reputation ranking 2023
- Medical Oncology #7 https://www.fdygs.com/news2023-1.aspx
-
West China Hospital, Sichuan University四川大学华西医院
Fudan specialty reputation ranking 2023
- Medical Oncology #8 https://www.fdygs.com/news2023-1.aspx
National key clinical specialty
- Medical Oncology (level A) https://wcums.scu.edu.cn/kxyan_jiu/gjlczdzk.htm
- Orthopedics (level A) https://wcums.scu.edu.cn/kxyan_jiu/gjlczdzk.htm
- Orthopedics (level A) https://wcums.scu.edu.cn/kxyan_jiu/gjlczdzk.htm
Also ranked: General Surgery #3, Thoracic Surgery #4, Urology #2 (tied) in the Fudan list.
Clinical trials (investigational treatments)
In addition to standard care, clinical research studies for Bone and soft tissue sarcoma may currently be open to participants in China. The treatments under study have not been approved by the regulator as standard therapy — they are clinical research, not routine treatment. Each record names the lead investigator and the hospital running the study. If you are interested, contact the hospital to ask about eligibility and choose whether to apply.
-
Study A Multicenter, Open, One-arm Phase II Study of Ranvastinib Mesylate Capsules in the Treatment of Advanced Bone and Soft Tissue Sarcoma After Chemotherapy Failure
- Lead investigator
- Wang Jiaqiang · associate chief physician
- Hospital
- Henan Cancer Hospital
- Status
- Recruiting
- Registry
- NCT05617859
-
Study ARTEMIS-002: A Phase 2, Multicenter, Open-label Study of Intravenous Administration of HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
- Hospital
- Peking University People's Hospital
- Status
- Recruiting
- Registry
- NCT05830123
-
Study A Phase I Clinical Study on the Safety, Tolerability, and Efficacy of KXV01 Injection in Patients With Advanced Solid Tumor (Including Osteosarcoma and Sarcoma)
- Hospital
- Shanghai Sixth People's Hospital
- Status
- Recruiting
- Registry
- NCT07596693
-
Study A Prospective, Single-arm, Multicenter Exploratory Clinical Study of Anlotinib Combined With Bempegaldesleukin and Conventional Chemoradiotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma.
- Hospital
- Jiangsu Province Hospital
- Status
- Not yet recruiting
- Registry
- NCT07156643
This page only shares publicly registered study information. It does not recommend or encourage joining any study. Participation is entirely voluntary and the risks of an unapproved treatment are unknown; contact the hospital directly for eligibility and informed-consent details.
Hospitals with a national key specialty record
Show the hospital records 55 hospitals with a key-specialty record
Each row is a hospital with a national key clinical specialty record in a specialty this condition is filed under. This is a record of published listings, not a recommendation and not a ranking.
55 hospitals with a matching national key specialty record.
Values written in Chinese are quoted as published by the source.
Questions about this condition
We cannot give medical advice, but we can answer questions about this page and about arranging treatment in China.
ICD codes
Show the code table 4 ICD codes
| Version | Code | Name in that version |
|---|---|---|
| ICD-10-WHO | C40 | Malignant neoplasm of bone and articular cartilage of limbs |
| ICD-10-WHO | C41 | Malignant neoplasm of bone and articular cartilage of other and unspecified sites |
| ICD-10-WHO | C47 | Malignant neoplasm of peripheral nerves and autonomic nervous system |
| ICD-10-WHO | C49 | Malignant neoplasm of other connective and soft tissue |
Rows are the WHO ICD-10 entries for this condition, quoted as published.
Source & evidence
- Source URL
- https://www3.ha.org.hk/cancereg/tc/icd10.html
- Source scheme
- https
- Source type
- Third-party compilation
- Evidence level
- A - said by a provincial health commission or university
- Retrieved on
- 2026-10-01